Optimal treatment of social phobia: Systematic review and meta-analysis

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 203-215

  Canton, John ^a   Scott, Kate M ^a   Glue, Paul ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antidepressant; Cognitive behavior therapy; Psychotherapy; Social anxiety disorder; Social phobia

Indexed keywords

ATOMOXETINE; BENZODIAZEPINE; BROFAROMINE; BROMAZEPAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

CHRONIC DISEASE; COGNITIVE THERAPY; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FOOD DRUG INTERACTION; HUMAN; LONG TERM CARE; PATIENT CARE; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW; SOCIAL PHOBIA;

EID: 84860868094     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S23317     Document Type: Review

References (109)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders, 4th ed. Washington DC: American Psychiatric Association; 2000.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1980.
3. Magee WJ, Eaton WW, Wittchen H-U, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(2):159-168.
4. Ruscio A, Brown T, Chiu W, Sareen J, Stein M, Kessler R. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008;38(1):15-28.
5. Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry. 2000;157(10):1606-1613.
6. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001; 158(12):1999-2007.
7. Davidson JR, Hughes D, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med. 1993;23(3):709-718.
8. DeWit DJ, Ogborne A, Offord D, MacDonald K. Antecedents of the risk of recovery from DSM-III-R social phobia. Psychol Med. 1999;29(3):569-582.
9. Chartier MJ, Hazen AL, Stein MB. Lifetime patterns of social phobia: a retrospective study of the course of social phobia in a nonclinical population. Depress Anxiety. 1998;7(3):113-121.
10. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49(4):282-288.
11. Schneier FR, Foose TE, Hasin DS, et al. Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2010;40(6):977-988.
12. Kessler RC, Ustun TB, editors. The WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental Disorders. New York, NY: Cambridge University Press; 2008.
13. Schneier FR. Pharmacotherapy of social anxiety disorder. Expert Opin Pharmacother. 2011;12(4):615-625.
14. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71(7): 839-854.
15. Acarturk C, Cuijpers P, van Straten A, de Graaf R. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009;39(2):241-254.
16. Powers MB, Sigmarsson S, Emmelkamp PMG. A meta-analytic review of psychological treatments for social anxiety disorder. Int J Cogn Ther. 2008;1(2):94-113.
17. Ganasen K, Ipser J, Stein D. Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin North Am. 2010;33(3): 687-699.
18. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010;12(5):471-477.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised. Rockville, MD: National Institute of Mental Health; 1976.
20. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Rüther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8(3):175-187.
21. Stein DJ, Ipser J, van Balkom AJ. Pharmacotherapy for social anxiety disorder. Cochrane Database Syst Rev. 2000;4.
22. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280(8): 708-713.
23. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005a;62(2):190-198.
24. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66-74.
25. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004;65(2):222-229.
26. Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19(4):241-248.
27. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175(2):120-126.
28. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19(6):387-396.
29. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100(3):193-198.
30. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder. Br J Psychiatry. 2005;186(3):222-226.
31. Zhang W, Connor KM, Davidson JRT. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005;19(5):551-553.
32. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22(3):257-262.
33. Davidson JRT, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004a;61(10):1005-1013.
34. van Vliet I, Boer J, Westenberg H. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology. 1994;115(1):128-134.
35. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156(5):756-760.
36. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004b;24(2):118-125.
37. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275-281.
38. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(7):785-792.
39. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179(1):23-30.
40. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66(10):1270-1278.
41. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol. 1996;16(3):218-222.
42. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002;59(12):1111-1118.
43. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20(6):636-644.
44. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a metaanalysis. J Affective Dis. 2010;123(1):9-16.
45. Simon NM, Worthington JJ, Moshier SJ, et al. Generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010;15(7):436-443.
46. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177(3):280-288.
47. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(5):488-496.
48. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005b;66(2): 238-247.
49. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry. 1993; 163 Suppl 21:30-34.
50. Versiani M, Nardi A, Mundim F, Alves A, Liebowitz M, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992;161(3):353-360.
51. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49(4):290-300.
52. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998;55(12):1133-1141.
53. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry. 1991;48(10):938-945.
54. Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol. 1988;8(4):279-283.
55. Nutt DJ, Glue P. Monoamine oxidase inhibitors: rehabilitation from recent research? Br J Psychiatry. 1989;154:287-291.
56. Van Vliet IM, den Boer JA, Westenburg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol. 1992;2(1):21-29.
57. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997;17(4):255-260.
58. Fahlén T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase A and serotonin uptake inhibitor brofaromine: a double-blind placebocontrolled study. Acta Psychiatr Scand. 1995;92(5):351-358.
59. Stein DJ, Cameron A, Amrein R, et al. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002;17(4):161-170.
60. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998;172(1):70-77.
61. Oosterbaan DB, van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: a controlled study. Clin Psychol Psychother. 2001;8(4):263-273.
62. Noyes RJ, Moroz G, Davidson JRT, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997;17(4):247-254.
63. Katschnig H. Moclobemide in social phobia. Eur Arch Psychiatry Clin Neurosci. 1997;247(2):71-80.
64. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998;18(2):132-135.
65. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977;Suppl 5: 116-123.
66. Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009;29(6):561-564.
67. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(6):580-583.
68. Schutters SIJ, Van Megen HJGM, Van Veen JF, Denys DAJP, Westenberg HGM. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25(5):302-304.
69. Van Ameringen M, Mancini C, Oakman J, et al. Nefazodone in the t{stroke}reatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68(2):288-295.
70. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol. 2007;27(3):263-272.
71. 2+ channel [alpha] 2 [delta] ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28(2):75-82.
72. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341-348.
73. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141-149.
74. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26(4):213-220.
75. Glue P, Loan A, Gale C. New prospects for the drug treatment of generalized anxiety disorder: a systematic review. Curr Drug Ther. 2010;5(2):86-94.
76. Stein M, Ravindran L, Simon N, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010;71(5):627-631.
77. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18(3):169-172.
78. Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004;65(12):1674-1678.
79. Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007;22(4):241-244.
80. Benítez CIP, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatric Psych. 2008;16(1):5-13.
81. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety. 2005;22(2):59-67.
82. Davidson JR, Potts N, Richichi E, Krishnan KR. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13(6):423-428.
83. Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C. Doubleblind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr. 1997;46(3):167-171. Portuguese.
84. Connor KM, Davidson JRT, Potts NLS, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998;18(5):373-378.
85. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65(2):244-248.
86. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry. 2011;168(10):1057-1065.
87. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JRT. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365-368.
88. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1464-1469.
89. Davidson J. Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl. 2003;417:65-71.
90. Koszycki D, Benger M, Shlik J, Bradwejn J. Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007;45(10):2518-2526.
91. Borge F-M, Hoffart A, Sexton H, Clark DM, Markowitz JC, McManus F. Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord. 2008;22(6):991-1010.
92. Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(7):692-700.
93. Hedman E, Andersson G, Ljótsson B, et al. Internet-based cognitive behavior therapy vs cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PloS One. 2011;6(3):e18001.
94. Andrews G, Davies M, Titov N. Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry. 2011;45(4):337-340.
95. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71(6):1058-1067.
96. Liebowitz MR, Heimberg RG, Schneier FR, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: Long term outcome. Depress Anxiety. 1999;10(3):89-98.
97. Haug TT, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003;182(4):312-318.
98. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286-295.
99. Prasko J, Dockery C, Horácek J, et al. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuroendocrinol Lett. 2006;27(4):473-481.
100. Knijnik DZ, Blanco C, Salum GA, et al. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry. 2008;23(8):567-574.
101. Scott K, McGee M, Oakley Browne M, Wells JE. Mental disorder comorbidity in Te Rau Hinengaro: the New Zealand Mental Health Survey (NZMHS). Aust N Z J Psychiatry. 2006;40(10):875-881.
102. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract. 2009;63(7):1085-1094.
103. Curran VH. Benzodiazepines, memory and mood: a review. Psychopharmacology. 1991;105(1):1-8.
104. Glue P, Gale C. Off-label use of quetiapine in New Zealand - a cause for concern? N Z Med J. 2011;124(1336):10-13.
105. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry. 2008;20(1):15-20.
106. Rush A, Trivedi M, Wisniewski S, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163(11):1905-1917.
107. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
108. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-267.
109. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.